BioMérieux BioMérieux Receives CE Mark for Vitek Clinical Microbiology Mass Spec System The company said it plans to launch the instrument in selected European and Asian markets in the second half of 2021, with a global launch planned for 2022. BioMérieux Reports 10 Percent Q1 Revenue Growth, Lowers Full-Year Guidance The firm now guides for neutral to mid-single digit growth in 2021, decreased from a prior range of 5 percent to 8 percent growth. BioFire Dx Receives First FDA Marketing Clearance for SARS-CoV-2 Respiratory Panel The test is the first COVID-19 assay to transition from Emergency Use Authorization to a cleared regulatory status. BioMérieux Reports 21 Percent Revenue Growth in Q4 The firm guided for 2021 revenue growth of between 5 percent and 8 percent, citing "a persistently uncertain business environment." In Brief This Week: Natera, Sync for Genes, Castle Biosciences, BioMérieux, PathogenDx, More News items for the week of Dec. 21, 2020. Dec 16, 2020 BioMérieux Nabs CE Mark for RT-PCR SARS-CoV-2, Influenza A/B Assay Dec 8, 2020 BioMérieux Coronavirus Test Gets FDA OK for Use With Pooled Samples Oct 22, 2020 BioMérieux Q3 Revenues Increase 21 Percent Sep 8, 2020 As Flu Season Nears, Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza Premium Sep 2, 2020 BioMérieux Posts 16 Percent Sales Growth for First Half of 2020 Jul 21, 2020 AdvaMed Partners With Dx Companies to Create National COVID-19 Supply Registry Jul 15, 2020 BioMérieux BioFire Respiratory Panel With SARS-CoV-2 Target Nabs CE Mark Jul 9, 2020 BioMérieux Reports 62 Percent BioFire FilmArray Sales Growth in Preliminary Q2 Release May 19, 2020 BioMérieux's BioFire Pneumonia Panel Could Improve Care, Find Secondary Infection in COVID-19 Cases Premium May 8, 2020 BioMérieux Gets US Emergency Use Authorization for SARS-CoV-2 R-Gene MDx May 4, 2020 BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA Emergency Use Authorization Apr 16, 2020 BioMérieux Reports 22 Percent Q1 Revenue Growth, Withdraws Full-Year Guidance Mar 24, 2020 BioMérieux Rapid Coronavirus Test Gets FDA Emergency Use Authorization Mar 20, 2020 Commercial Coronavirus Test Developers Tweak Timelines, EUA Plans in Light of Loosened FDA Guidance Mar 12, 2020 Jury Rules in Favor of Hologic, Grifols in BioMérieux Patent Infringement Lawsuit Mar 12, 2020 DIAMONDS Project Using New Classification Approach to Develop Rapid Infectious Disease Tests Premium Feb 26, 2020 BioMérieux Reports 11 Percent Revenue Growth in Q4 Jan 14, 2020 BioMérieux Submits 43-Target BCID2 Test to FDA Jan 10, 2020 The Decade In Proteomics: Most Significant New Applications Premium Oct 22, 2019 BioMérieux Q3 Revenues Up 13 Percent Load More Breaking News Alzheimer's Disease Phosphoproteomics Study Uncovers Signaling Abnormalities Genetic Analysis of H. Pylori Indicates Americas Colonized in One Main Migration Event BillionToOne Raises $55M in Series B Financing GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana Top Five Articles on GenomeWeb Last Week: Illumina, Liquid Biopsy, Thermo Fisher Scientific, and More Becton Dickinson Sues Beckman Coulter Over Cell Analysis, Sorting IP The Scan Another Resignation According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug. Novavax Finds Its Vaccine Effective Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19. Can't Be Used The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports. PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.